Skip to main content
For US Healthcare Professionals Only
Quick Links
Prescribing information
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
REMS
FINTEPLA® (fenfluramine)
ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
Report an Adverse Event or Product Complaint
Email
1-844-599-CARE (2273)
Connect With an MSL
Connect With Us
Main navigation
Home
Our Science
Overview
Clinical Pipeline
Opportunities for Investigators
Scientific Education
Overview
Dermatology
Epilepsy
Rare Disease
Rheumatology
Podcasts
Independent Medical Education
Congress Materials
Publications
Medical Information
Overview
Submit Medical Inquiry
HCP Resources
Overview
Search HCP Resources
Slide Library
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
REMS
FINTEPLA® (fenfluramine)
ZILBRYSQ® (zilucoplan)
Home
Congress Materials
Fall Clinical Dermatology Conference, 2026
Sex-specific and age-adjusted prevalence of hidradenitis suppurativa: Results from Komodo US claims data suggest sex parity of HS symptoms
Back to search results
Sex-specific and age-adjusted prevalence of hidradenitis suppurativa: Results from Komodo US claims data suggest sex parity of HS symptoms
View PDF
For US Healthcare Professionals Only